SCHEMBL3769405

SCHEMBL3769405

COc1ccc(C(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c(OC)c1

nearest known ligand 0.77

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 3/20 0.54
ALDH1A1 P00352 3/20 0.50
TSHR P16473 2/20 0.50
KMT2A Q03164 1/20 0.50
GAA P10253 1/20 0.50
KDM4E B2RXH2 2/20 0.49
HSD11B1 P28845 1/20 0.49
HTT P42858 1/20 0.48
RAB9A P51151 2/20 0.48
PKM P14618 1/20 0.47
NPC1 O15118 1/20 0.46
OXTR P30559 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3772205 0.92 ALDH1A1 (0.50) KDM2BALDH1A1TSHRKMT2AKDM4E
SCHEMBL3773691 0.89 KDM4E (0.51) ALDH1A1TSHRGAAKDM4EHTT
SCHEMBL3767550 0.87 ALDH1A1 (0.49) ALDH1A1TSHRKMT2AKDM4ERAB9A
SCHEMBL3770107 0.86 KDM4E (0.66) ALDH1A1TSHRKMT2AGAAKDM4E
SCHEMBL3780644 0.86 ALDH1A1 (0.55) KDM2BALDH1A1TSHRKMT2AGAA
SCHEMBL13005925 0.84 KMT2A (0.57) KDM2BALDH1A1TSHRKMT2AGAA
SCHEMBL3774233 0.84 RAB9A (0.57) KDM2BALDH1A1TSHRKMT2AGAA
SCHEMBL3770901 0.84 ALDH1A1 (0.53) KDM2BALDH1A1TSHRKMT2AGAA
SCHEMBL3780478 0.83 KDM4E (0.51) ALDH1A1TSHRKDM4ERAB9ANPC1
SCHEMBL3773990 0.83 ALDH1A1 (0.54) ALDH1A1TSHRKMT2AGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM2B 772/4885ALDH1A1 1210/4885TSHR 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.